HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAapproval65% confidence

FDA Approves First Generics of Gilotrif (afatinib) Tablets

Source: FDA

Why This Matters

Why this matters: provides agency context on approval that may shape timing or evidence expectations for BioNTech SE.

Regulatory Analysis

Supporting Context

Therapeutic area
Oncology · Monoclonal Antibody
Sub-indication
General

Related signal: Genmab's GEN1042 Trial Evaluates Anti-tumor Activity in Solid Tumors

Source

View source document

Related Signal

Open signal — Genmab's GEN1042 Trial Evaluates Anti-tumor Activity in Solid Tumors
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.